Skip to main content
SpringerLink
Log in

Pilzinfektionen bei hämatologischen Patienten und nach Blutstammzelltransplantation

Prophylaxe und Therapie

Fungal infections in hematology patients and after blood stem cell transplantation

Prophylaxis and treatment

  • Übersichten
  • Published:
Medizinische Klinik - Intensivmedizin und Notfallmedizin Aims and scope Submit manuscript

Zusammenfassung

Invasive Pilzinfektionen stellen ein großes Risiko für Patienten mit lang andauernder Neutropenie bzw. Immunsuppression nach Stammzelltransplantation dar. Zur Senkung der assoziierten Morbidität und Mortalität wird häufig eine antimykotische Prophylaxe eingesetzt. An antimykotischen Substanzklassen stehen Azole (z. B. Fluconazol, Itraconazol, Posaconazol), Echinocandine (Caspofungin, Micafungin) und Amphotericin B zur Verfügung. Auf die aktuelle Studienlage zur Prophylaxe und Therapie bei hämatologischen Patienten wird eingegangen, ein besonderer Fokus liegt auf der Diskussion empirische vs. präemptive Therapie.

Abstract

Patients with prolonged neutropenia or immunosuppression after stem cell transplantation are at a high risk of developing invasive fungal infections. Antimycotic prophylaxis is used to reduce the associated morbidity and mortality. The following classes of antimycotic agents are currently available: azoles (e.g., fluconazole, itraconazole, posaconazole), echinocandins (caspofungin, micafungin), and amphotericin B.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Bohme A, Ruhnke M, Buchheidt D et al (2009) Treatment of invasive fungal infections in cancer patients – recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 88:97–110

    Article  PubMed  Google Scholar 

  2. Cordonnier C, Mohty M, Faucher C et al (2008) Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 31:135–141

    Article  PubMed  CAS  Google Scholar 

  3. Cordonnier C, Pautas C, Maury S et al (2009) Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48:1042–1051

    Article  PubMed  CAS  Google Scholar 

  4. Cornely OA, Bohme A, Buchheidt D et al (2003) Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S186–S200

    Article  PubMed  Google Scholar 

  5. Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359

    Article  PubMed  CAS  Google Scholar 

  6. De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821

    Article  Google Scholar 

  7. El-Cheikh J, Faucher C, Furst S et al (2007) High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 39:301–306

    Article  PubMed  CAS  Google Scholar 

  8. Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93

    Article  PubMed  Google Scholar 

  9. Glasmacher A, Cornely O, Ullmann AJ et al (2006) An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 57:317–325

    Article  PubMed  CAS  Google Scholar 

  10. Glasmacher A, Cornely OA, Orlopp K et al (2006) Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J Antimicrob Chemother 57:127–134

    Article  PubMed  CAS  Google Scholar 

  11. Goodman JL, Winston DJ, Greenfield RA et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851

    Article  PubMed  CAS  Google Scholar 

  12. Hashino S, Morita L, Takahata M et al (2008) Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 87:91–97

    Article  PubMed  Google Scholar 

  13. Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415

    Article  PubMed  CAS  Google Scholar 

  14. Maertens J, Marchetti O, Herbrecht R et al (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 46:709–718

    Article  PubMed  CAS  Google Scholar 

  15. Maertens J, Theunissen K, Verhoef G et al (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41:1242–1250

    Article  PubMed  CAS  Google Scholar 

  16. Mattiuzzi GN, Alvarado G, Giles FJ et al (2006) Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50:143–147

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Nihtinen A, Anttila VJ, Ruutu T et al (2012) Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis. Transpl Infect Dis 14:24–32

    Article  PubMed  CAS  Google Scholar 

  18. Pagano L, Caira M, Candoni A et al (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068–1075

    PubMed  Google Scholar 

  19. Pfaller MA, Pappas PG, Wingard JR (2006) Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 43:S3–S14

    Article  CAS  Google Scholar 

  20. Prentice HG, Kibbler CC, Prentice AG (2000) Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110:273–284

    Article  PubMed  CAS  Google Scholar 

  21. Slavin MA, Osborne B, Adams R et al (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J Infect Dis 171:1545–1552

    Article  PubMed  CAS  Google Scholar 

  22. Ullmann AJ, Lipton JH, Vesole DH et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335–347

    Article  PubMed  CAS  Google Scholar 

  23. Van Burik JA, Ratanatharathorn V, Stepan DE et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407–1416

    Article  Google Scholar 

  24. Wingard JR, Carter SL, Walsh TJ et al (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116:5111–5118

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Interessenkonflikt

Die korrespondierende Autorin weist für sich und ihren Koautor auf folgende Beziehung/en hin: Dr. Thomas Schmitt: Es bestehen keine relevanten Interessenkonflikte. Priv.-Doz. Dr. Gerlinde Egerer: Vortragshonorare von Gilead, Pfizer und MSD.

Author information

Authors and Affiliations

  1. Medizinische Klinik Abt. V Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland

    G. Egerer & T. Schmitt

Authors
  1. G. Egerer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Egerer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Egerer, G., Schmitt, T. Pilzinfektionen bei hämatologischen Patienten und nach Blutstammzelltransplantation. Med Klin Intensivmed Notfmed 109, 526–530 (2014). https://doi.org/10.1007/s00063-013-0238-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-013-0238-y

Schlüsselwörter

Keywords

Search

Navigation